Published in PLoS One on November 20, 2014
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
A new depression scale designed to be sensitive to change. Br J Psychiatry (1979) 36.40
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.20
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology (1998) 8.73
Schizophrenia. Lancet (2009) 8.14
Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry (2007) 6.20
A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res (2005) 5.78
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet (2012) 4.59
Global assessment of functioning. A modified scale. Psychosomatics (1995) 4.48
Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry (2009) 4.44
International consensus study of antipsychotic dosing. Am J Psychiatry (2010) 3.39
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
Early intervention for psychosis. Cochrane Database Syst Rev (2011) 3.04
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br J Psychiatry (1995) 2.60
Personality and coping. Annu Rev Psychol (2010) 2.60
Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry (2003) 2.41
Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry (2011) 2.24
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry (2008) 2.23
Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med (2007) 2.06
Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry (2008) 1.85
Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull (2008) 1.81
What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev (2009) 1.73
Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry (2010) 1.64
Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am (2005) 1.63
Neural correlates of memory for items and for associations: an event-related functional magnetic resonance imaging study. J Cogn Neurosci (2005) 1.61
Cognitive impairment in schizophrenia. Handb Exp Pharmacol (2012) 1.57
Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res (2012) 1.51
Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull (2011) 1.38
Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment (2012) 1.37
Turning it upside down: areas of preserved cognitive function in schizophrenia. Neuropsychol Rev (2009) 1.35
Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry (2010) 1.33
A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med (2006) 1.31
Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull (2012) 1.22
Neurocognition in schizophrenia. Curr Top Behav Neurosci (2010) 1.20
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res (2010) 1.16
Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry (1995) 1.15
Neuropsychological test profiles in schizophrenia and non-psychotic depression. Acta Psychiatr Scand (2006) 1.12
Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry (2007) 1.09
Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. Schizophr Res (2013) 1.06
Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res (2013) 1.06
Duration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data. Schizophr Res (2012) 0.97
The need for routine physical health care in schizophrenia. Eur Psychiatry (2010) 0.97
Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder. Bipolar Disord (2013) 0.96
Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years. Schizophr Res (2012) 0.96
Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry (2012) 0.96
Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci (2012) 0.95
The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. Eur Psychiatry (2011) 0.94
Management of physical health in patients with schizophrenia: practical recommendations. Eur Psychiatry (2010) 0.93
Temporal association of stress sensitivity and symptoms in individuals at clinical high risk for psychosis. Psychol Med (2012) 0.93
AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology (2011) 0.92
A systematic review of attachment and psychosis: measurement, construct validity and outcomes. Acta Psychiatr Scand (2013) 0.89
Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework. Psychopathology (2012) 0.89
Clinical and sociodemographic comparison of people at high-risk for psychosis and with first-episode psychosis. Acta Psychiatr Scand (2012) 0.88
Neurocognitive functioning in schizophrenia and during the early phases of psychosis: targeting cognitive remediation interventions. Biomed Res Int (2013) 0.85
Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des (2012) 0.85
Personality dimensions in schizophrenia: associations with symptoms and coping concurrently and 12 months later. Psychopathology (2007) 0.84
Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr Res (2010) 0.83
Premorbid adjustment in schizophrenia and schizoaffective disorder. Psychiatry Res (2009) 0.83
Sustained and transient attention in the continuous performance task. J Clin Exp Neuropsychol (2006) 0.82
Differences between first episode schizophrenia and schizoaffective disorder. Schizophr Res (2013) 0.81
Relative contributions of gender and traumatic life experience to the prediction of mental disorders in a sample of incarcerated offenders. Behav Sci Law (2012) 0.81
Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol Med (2011) 0.80
Correlation of cognitive functions with some aspects of illness, treatment and social functioning in recurrently hospitalized schizophrenic patients. Coll Antropol (2011) 0.79
Initial predictors of outcome in an early intervention in psychosis service. Early Interv Psychiatry (2013) 0.76
Psychosis Incident Cohort Outcome Study (PICOS). A multisite study of clinical, social and biological characteristics, patterns of care and predictors of outcome in first-episode psychosis. Background, methodology and overview of the patient sample. Epidemiol Psychiatr Sci (2012) 0.76
Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorder. BMC Psychiatry (2016) 0.75
Suicide in Recent Onset Psychosis Revisited: Significant Reduction of Suicide Rate over the Last Two Decades - A Replication Study of a Dutch Incidence Cohort. PLoS One (2015) 0.75